CEVA INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CEVA INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $87.51M | Mar 1, 2018 |
| FY2017 | Dec 31, 2016 | $72.65M | Mar 1, 2018 |
| FY2017 | Dec 31, 2015 | $59.50M | Mar 1, 2018 |
| FY2016 | Dec 31, 2014 | $50.81M | Mar 10, 2017 |
| FY2015 | Dec 31, 2013 | $48.90M | Mar 11, 2016 |
| FY2014 | Dec 31, 2012 | $53.68M | Mar 13, 2015 |
| FY2013 | Dec 31, 2011 | $60.24M | Mar 14, 2014 |
| FY2012 | Dec 31, 2010 | $44.91M | Mar 15, 2013 |
| FY2011 | Dec 31, 2009 | $38.47M | Mar 15, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.44M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $94.17M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $85.77M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $105.45M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $103.45M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $89.58M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $77.05M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $69.93M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $80.55M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $66.57M | Mar 4, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($10.64M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($8.79M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($11.88M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($23.18M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $396.0K | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($2.38M) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $28.0K | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $574.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $17.03M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $13.10M | Mar 4, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.35M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($7.55M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($13.47M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $3.90M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $7.04M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | ($763.0K) | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | ($1.92M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($1.25M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $15.87M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $14.39M | Mar 4, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $74.83M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $71.62M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $72.69M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $70.32M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $69.09M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $62.01M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $52.84M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $47.76M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $40.39M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $30.84M | Mar 4, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.36M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $3.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($6.33M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $6.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $25.80M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $15.16M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $9.67M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $8.61M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $24.47M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $14.46M | Mar 4, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.92M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $2.96M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $2.88M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $3.50M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.19M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $2.94M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $3.46M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $3.32M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $4.14M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $2.39M | Mar 4, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $388.26M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $308.95M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $304.09M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $308.44M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $328.66M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $306.95M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $297.02M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $277.26M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $276.81M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $242.50M | Mar 1, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $336.46M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $266.56M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $264.34M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $258.87M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $276.73M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $260.89M | Mar 7, 2024 |
| FY2022 | Dec 31, 2019 | $251.16M | Mar 1, 2023 |
| FY2021 | Dec 31, 2018 | $245.88M | Mar 1, 2022 |
| FY2020 | Dec 31, 2017 | $244.67M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $211.55M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $58.31M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $58.31M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $58.31M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $56.79M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $74.78M | Mar 1, 2023 |
| FY2022 | Dec 31, 2020 | $51.07M | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | $51.07M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $46.61M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $46.61M | Feb 28, 2020 |
| FY2017 | Dec 31, 2016 | $46.61M | Mar 1, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($24.0K) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $11.19M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $20.17M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $32.16M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $55.49M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | $57.35M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $62.43M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $62.85M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $53.87M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | $39.43M | Mar 1, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.59M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $18.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $23.29M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $20.12M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $32.64M | Mar 7, 2024 |
| FY2021 | Dec 31, 2020 | $21.14M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $22.80M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $22.26M | Feb 28, 2020 |
| FY2019 | Dec 31, 2017 | $21.74M | Feb 28, 2020 |
| FY2019 | Dec 31, 2016 | $18.40M | Feb 28, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 4, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | (1) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Mar 1, 2023 |
| FY2021 | Dec 31, 2019 | 0 | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | 0 | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | 0 | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | 0 | Mar 4, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 27.51M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 23.63M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 23.44M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 23.22M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 22.98M | Mar 1, 2023 |
| FY2021 | Dec 31, 2020 | 22.26M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | 21.84M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 21.79M | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | 21.79M | Mar 4, 2019 |
| FY2017 | Dec 31, 2016 | 21.27M | Mar 1, 2018 |